Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy

Climacteric

Volumn 9, Issue 6, 2006, Pages 452-458

  Maffei, S ^a   Mercuri, A ^a   Prontera, C ^a   Zucchelli, G C ^a   Vassalle, C ^a,b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b CNR   (Italy)

Author keywords

Catecholamines; Hormone replacement therapy; Low density lipoprotein; Mean blood pressure; Menopause; Nitric oxide; Oxidative stress; Prostacyclin

Indexed keywords

8 ISOPROSTANE; ADRENALIN; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CHOLESTEROL; DYDROGESTERONE; ESTRADIOL; ESTROGEN; FOLLITROPIN; LIPID; NITRATE; NITRITE; NORADRENALIN; PROSTACYCLIN; VASOACTIVE AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM CELL; ESTROGEN THERAPY; FEMALE; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; NORMAL HUMAN; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

6-KETOPROSTAGLANDIN F1 ALPHA; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHOLESTEROL, LDL; DINOPROST; DYDROGESTERONE; EPINEPHRINE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; MIDDLE AGED; NITRATES; NITRITES; NOREPINEPHRINE; OXIDATIVE STRESS; POSTMENOPAUSE;

EID: 33750605292     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601014752     Document Type: Article

References (24)

1. Wenger NK. Clinical characteristics of coronary heart disease in women: emphasis on gender differences. Cardiovasc Res 2002;53:558-67
2. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 2002;53:550-7
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-713
4. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109
5. Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 2005;84:1589-601
6. Koh KK. Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy? Int J Cardiol 2003;87:1-8
7. Maffei S, Mercuri A, Zucchelli GC, Vassalle C. Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women. Int J Cardiol 2006;107:194-9
8. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after HRT in postmenopausal women. Clin Sci (London) 2001;101:447-53
9. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004;43:918-23
10. Del Rio G, Velardo A, Zizzo G, et al. Effect of estradiol on the sympathoadrenal response to mental stress in normal men. J Clin Endocrinol Metab 1994;79:836-40
11. Larsson B, Andersson KE, Batra S, Mattiasson A, Sjogren C. Effects of estradiol on norepinephrine-induced contraction, alpha adrenoceptor number and norepinephrine content in the female rabbit urethra. J Pharmacol Exp Ther 1984;229:557-63
12. Ma ZQ, Bondiolotti GP, Olasmaa M, et al. Estrogen modulation of catecholamine synthesis and monoamine oxidase A activity in the human neuroblastoma cell line SK-ER3. J Steroid Biochem Mol Biol 1993;47:207-311
13. Colucci WS, Gimbrone MA Jr, McLaughlin MK, Halpern W, Alexander RW. Increased vascular catecholamine sensitivity and alpha-adrenergic receptor affinity in female and estrogen-treated male rats. Circ Res 1982;50:805-11
14. Klangkalya B, Chan A. The effects of ovarian hormones on beta-adrenergic and muscarinic receptors in rat heart. Life Sci 1988;42:2307-14
15. Gandia L, Casado LF, Lopez MG, Garcia AG. Separation of two pathways for calcium entry into chromaffin cells. Br J Pharmacol 1991;103:1073-8
16. Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial. Menopause 1998;5:157-62
17. Ossewaarde ME, Bots ML, Bak AA, et al. Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women. Maturitas 2001;39:209-16
18. Balci H, Altunyurt S, Acar B, Fadiloglu M, Kirkali G, Onvural B. Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women. Maturitas 2005;50:289-93
19. Hayashi T, Yamada K, Esaki T, et al. Estrogen increases endothelial nitric oxide by a receptormediated system. Biochem Biophys Res Commun 1995;214:847-55
20. Thomson CA, Giuliano AR, Shaw JW, et al. Diet and biomarkers of oxidative damage in women previously treated for breast cancer. Nutr Cancer 2005;51:146-54
21. Chen G, Heilbrun LK, Venkatramanamoorthy R, et al. Effects of low-fat and/or high-fruit-and-vegetable diets on plasma levels of 8-isoprostane-F2alpha in the Nutrition and Breast Health Study. Nutr Cancer 2004;50:155-60
22. Serrano Rios M. Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998;28:14-17
23. Vassalle C, Petrozzi L, Botto N, Andreassi MG, Zucchelli GC. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. J Intern Med 2004;256:308-15
24. Unfer TC, Conterato GM, da Silva JC, Duarte MM, Emanuelli T. Influence of hormone replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chim Acta 2006;369:73-7